combination of both hormones were infused over 360 min on different days in randomized order (3) . Additionally, eight male overweight subjects with normal glucose tolerance (49.9 6 3.2 years, BMI 32.9 6 0.7 kg/m 2 ) were given GIP infusion (2 pmol z kg 21 z min 21 ) and placebo (isotonic saline) infusion for 240 min (4) . In cohort I, intact, biologically active GIP and GLP-1 were measured as described previously (3) . In cohort II, total GIP was determined by commercial ELISA kit (Linco Research, St. Charles, MO). Midregional pro-ANP (MR-proANP) was measured with an immunoassay (MR-proANP LIA; B.R.A.H.M.S GmbH, Hennigsdorf, Germany).
In subjects with type 2 diabetes, exogenous GIP elevated the total concentrations of GIP to steady-state levels of ;530 pmol/L and concentrations of intact, biologically active GIP to 225 pmol/L (3). In the experiments with GLP-1 infusion, plasma concentrations of total GLP-1 increased to steady-state levels of ;145 pmol/L and concentrations of intact, biologically active GLP-1 to 20 pmol/L (3). Plasma MR-proANP concentrations decreased with placebo and exogenous GLP-1 administration over the duration of the experiments (Fig. 1A) . With exogenous GIP, a slight reduction in MR-proANP concentrations was observed in the last hour of the infusion. Coinfusion of GLP-1 and GIP did not further lower MR-proANP concentrations. No difference in MR-proANP concentrations was observed between the experiments.
In healthy overweight subjects, total GIP plasma concentrations during infusion were ;120 pmol/L compared with ;5 pmol/L during saline infusion. MR-proANP concentrations decreased with placebo and exogenous GIP infusion over the duration of the experiments (Fig. 1B) . No difference in circulating MR-proANP levels between GIP and placebo infusion was observed.
We show that pharmacological doses of GIP and GLP-1, alone or in combination, are unable to stimulate ANP secretion, measured as circulating MRproANP in subjects with type 2 diabetes. In healthy overweight volunteers, a time course of MR-proANP changes toward lower concentrations during the tests. Our results confirm in part a recently published report on the exogenous application of GLP-1 in healthy men (2) . Thus, the GLP-1-ANP axis seems to be species-specific (observed solely in mice) (2) . Moreover, decreases in MRproANP levels were observed during a meal test (5) , which may reflect the regulation of MR-proANP by other mealrelated factors different from known incretin hormones or diurnal changes of natriuretic peptide levels throughout the day. Limitations of our study are the rather small number of patients studied and the short duration of exposure to incretins.
In conclusion, our data cannot confirm the existence of an incretin-ANP axis in humans. 
